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Abstract
Objective: HIV and type 2 diabetes are known risk factors for albuminuria, but no previous reports have characterized
albuminuria in HIV-infected patients with diabetes.
Research Design and Methods: We performed a cross-sectional study including 73 HIV-infected adults with type 2
diabetes, 82 HIV-infected non-diabetics, and 61 diabetic control subjects without HIV. Serum creatinine .1.5 mg/dL was
exclusionary. Albuminuria was defined as urinary albumin/creatinine ratio .30 mg/g.
Results: The prevalence of albuminuria was significantly increased among HIV-infected diabetics (34% vs. 13% of HIV non-
diabetic vs. 16% diabetic control, p=0.005). HIV status and diabetes remained significant predictors of albuminuria after
adjusting for age, race, BMI, and blood pressure. Albumin/creatinine ratio correlated significantly with HIV viral load (r=0.28,
p=0.0005) and HIV-infected subjects with albuminuria had significantly greater cumulative exposure to abacavir (p=0.01).
In an adjusted multivariate regression analysis of HIV-infected subjects, the diagnosis of diabetes (p=0.003), higher HIV viral
load (p=0.03) and cumulative exposure to abacavir (p=0.0009) were significant independent predictors of albuminuria.
Conclusions: HIV and diabetes appear to have additive effects on albuminuria which is also independently associated with
increased exposure to abacavir and HIV viral load. Future research on the persistence, progression and management of
albuminuria in this unique at-risk population is needed.
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Introduction
Kidney disease is an important contributor to HIV/AIDS-
related morbidity and mortality. As the life expectancy of HIV-
infected patients increases with the use of antiretroviral therapy,
chronic medical conditions such as renal failure are increasingly
prevalent [1,2,3]. In addition, type 2 diabetes is increased among
persons living with HIV and is associated with cumulative
exposure to antiretroviral therapy [4,5,6]. Though the influences
of both diabetes and HIV infection on kidney disease are well-
recognized, there is very little known about kidney disease among
HIV-infected individuals with type 2 diabetes.
Albuminuria is a marker of kidney damage, and is associated
with increased cardiovascular disease and renal mortality and
morbidity [7,8,9]. Prior to the widespread use of highly active
antiretroviral therapy (HAART), studies identified a strikingly high
prevalence of microalbuminuria (defined as urine albumin to
creatinine ratio greater than 30 mg/g, but less than 300 mg/g),
ranging from 19% to 30% among HIV-infected populations
[10,11]. More recent investigations of microalbuminuria in the
post-HAART era found a prevalence between 8.7% and 11%
among persons living with HIV [12,13]. Albuminuria is common
in type 2 diabetes in the absence of HIV. In one large longitudinal
cohort of adults with type 2 diabetes, 25% of participants had
microalbuminuria ten years after the diagnosis of diabetes [14].
Given the increased risk of microalbuminuria associated with both
HIV and diabetes, we evaluated a cohort of HIV-infected adults
with type 2 diabetes to assess the prevalence of albuminuria, as
compared to control groups with type 2 diabetes without HIV-
infection and HIV-infection without diabetes.
Materials and Methods
Subjects
Subjects were patients who attended HIV clinic at the
National Institute of Allergy and Infectious Diseases (NIAID)
outpatient clinic in Bethesda, MD or the Washington Hospital
Center Infectious Diseases clinic in Washington, DC between
March 2007 and February 2009. Potentially eligible participants
were notified of the available research studies at routine clinic
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3appointments and returned for subsequent research visits if
interested. Participants were 73 HIV-infected adults with type 2
diabetes (defined by one or more of the following: documented
diagnosis of type 2 diabetes, ICD9 codes 250.0–250.9, fasting
plasma glucose $ 126 mg/dL on 2 or more occasions, and/or
casual plasma glucose $ 200 mg/dL and the presence of
symptoms; subjects with type 1 diabetes were excluded) and 82
HIV-infected adults without diabetes or hyperglycemia (fasting
glucose ,110 mg/dl, no random glucose .200 mg/dl in the
past 2 years, no known diagnosis of diabetes and not on
antihyperglycemic agents). Subjects with known current preg-
nancy, active opportunistic infection or malignancy, and known
end stage renal disease or creatinine .1.5 mg/dL were excluded
from participation. Subjects with HIV and diabetes were
enrolled in a study of the accuracy of hemoglobin A1c which
has been published previously [15]. Non-diabetic HIV-infected
participants were enrolled in a study of albuminuria, but only
baseline assessments were available for use in this analysis.
Specific matching strategies were not used for HIV-infected
subjects with or without diabetes. The study protocols were
approved by the NIAID, the National Institute of Diabetes and
Digestive and Kidney Diseases, and Medstar Research Institute
institutional review boards. Participants gave written informed
consent.
A physical exam and detailed medical history were completed
and blood and urine samples were collected. A complete history of
current and past antiretroviral therapy and current medications
was recorded for all HIV-infected subjects. Measurements
included serum creatinine, as well as urine albumin and creatinine.
Albuminuria was defined as a urine albumin/creatinine ratio of
.30 mg/g.
To obtain a non-HIV-infected control group with type 2
diabetes, data from 61 adults with type 2 diabetes were obtained
from MedStar Health’s electronic medical record system. Controls
were selected based on availability of clinical data needed to meet
eligibility criteria and were selected to match in age (+/2 5 years),
sex and racial distribution to the HIV-infected subjects with
diabetes. With the exception of HIV-related factors, exclusion
criteria were the same as those for HIV-infected participating
subjects. Control subjects were required to have type 2 diabetes,
and have urine albumin and urine creatinine measurements from
the same day as well as a documented serum creatinine
measurement not greater than 1.5 mg/dL within the past year.
Control data from the electronic medical records dated between
2007 and 2009 and included demographic characteristics,
duration of diabetes, medication use, blood pressure and body
mass index (BMI). Results of hemoglobin A1c and glycemia
determinations for a subset of the subjects were reported
previously [15].
Measurements
Samples collected for serum creatinine and urine albumin and
creatinine determinations were processed and analyzed at the NIH
Department of Laboratory Medicine (Bethesda, MD). Urine
albumin was determined via the Microalbumin (MALB) method,
based on a particle-enhanced turbidimetric inhibition immunoas-
say adapted to the Dimension clinical chemistry system (Dade
Behring, Neward, DE). Urine and serum creatinine measurements
were determined using the CREA method on the Dimension
clinical chemistry system (Dade Behring, Newark, DE).
Glomerular filtration rate (GFR) was calculated using the
Cockroft-Gault equation and based on participant ideal body
weight. All participants were required to have a creatinine
#1.5 mg/dL and therefore the Cockroft-Gault was used for its
performance in estimation of GFR in those with near normal
kidney function.
In addition, stored serum maintained at 280uC from the 73
HIV-infected subjects with diabetes was available and homocys-
teine, IL-6, high sensitivity C-reactive protein (hsCRP), and
cystatin C levels were measured. Cystatin C, hsCRP, and IL-6
levels were measured by standard ELISA assays (R&D Systems,
Minneapolis, MN). Homocysteine was measured using a standard
ELISA assay (Axis-Shield, Dundee, Scotland).
Laboratory results for the HIV-uninfected controls with
diabetes were extracted from the electronic medical record and
were completed at various MedStar facility laboratories using
standardized procedures.
Statistical Analysis
Clinical characteristics and demographic variables were com-
pared between groups by analysis of variance, and, where
significant, individual group comparisons were made using
student’s t-tests. Chi-square statistics were used for analyses of
categorical variables. Univariate linear and logistic regression
analyses were performed to identify relationships between clinical
variables, albuminuria, and serum biomarkers. Multivariate
regression analysis was completed that included age, race, sex,
blood pressure, angiotensin-converting enzyme inhibitors (ACE)
and angiotensin receptor blocker (ARB) use as well as BMI to
account for possible influences these factors may have had on the
prevalence of albuminuria. In a sub-analysis of only HIV-infected
participants, univariate and multivariate analyses were completed
to assess the relationship between HIV specific characteristics (e.g.
CD4+ T-cell count, HIV viral load and antiretroviral exposure)
and albuminuria. These multivariate analyses also included age,
sex and race. All antiretroviral agents used by 10 or more
participants were included in analyses. Non-normally distributed
variables (e.g. urinary albumin/creatinine ratio) were log trans-
formed to approximate a normal distribution. A two-tailed alpha
,0.05 was used to determine statistical significance. All values are
presented as mean (standard error of the mean, SEM) unless
otherwise indicated. Data were analyzed using SAS JMP Version
7.0 (SAS Cary, NC).
Results
Demographic and clinical characteristics of the 3 study groups
are summarized in Table 1. Participants with diabetes (with or
without HIV infection) were older, had higher BMI, were more
likely to be on an ACE or ARB and were more often African
American than the HIV-infected subjects without diabetes. The
HIV-infected subjects with diabetes had higher mean systolic
blood pressure than HIV-infected participants without diabetes,
but diastolic blood pressure did not differ between groups.
Serum creatinine and GFR were similar between all three study
groups.
Among the HIV-infected subjects, there was no significant
difference in mean duration of HIV, CD4 T cell count, or
duration of ARV therapy, however, those with diabetes and HIV
were more likely to be ARV naive (15% vs. 1%, p=0.0006), less
likely to be on ARVs currently (77% vs 94%, p=0.002), and less
likely to have an HIV viral load ,50 copies/ml (56% vs 81%,
p=0.0007). Among the subject groups with diabetes, there was
no difference between those with and those without HIV
infection in duration of diabetes or the use of insulin therapy.
HIV-infected subjects with diabetes had a lower hemoglobin A1c
compared to subjects with diabetes without HIV (7.160.2 vs
7.860.3, p=0.03) however, we have previously reported
Albuminuria in HIV and Diabetes
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infected subjects [15].
Albuminuria was detected in 34% (25/73) of the HIV-infected
subjects with diabetes, compared to 13% (11/82) in the HIV-
infected non-diabetic group and 16% (10/61) in the group with
diabetes and no HIV (overall x
2=10.8, p=0.005, Figure 1).
Macroalbuminuria (urine albumin/creatinine ratio .300 mg/g)
was relatively uncommon and noted in only 6 HIV-infected
subjects with diabetes, 1 HIV-infected subject without diabetes
and 3 subjects in the diabetes alone group (p=0.09). In univariate
regression analyses, urinary albumin/creatinine ratio increased
with increasing age (r=0.19, p=0.005) and increasing blood
pressure (systolic r=0.30, p,0.0001 and diastolic r=0.28,
p,0.0001). Among those with a diagnosis of type 2 diabetes,
hemoglobin A1c was significantly correlated with albumin/
creatinine ratio (r=0.22, p=0.01) and this remained significant
in the sub-group of HIV-infected subjects with diabetes (r=0.30,
p=0.006). The presence of albuminuria did not differ by race
(x
2=4.5, p=0.34) or sex (x
2=1.1, p=0.3). In a multivariate
logistic regression analysis, including age, race, sex, BMI, ACE/
ARB use and blood pressure, both HIV infection status (p=0.02)
and diabetes status (p=0.03) remained statistically significantly
associated with the presence of albuminuria. The urinary
albumin/creatinine ratio was also significantly increased in both
groups with diabetes compared to the HIV-infected subjects
without diabetes (Table 1).
Table 1. Demographic and Clinical Characteristics of Subjects with HIV, Diabetes and both HIV and Diabetes.
HIV+/Diabetes HIV+ Diabetes p-value
N7 3 8 2 6 1
Age (yrs) 52614 5 615 1 61 ,0.0001
a
0.9
b
,0.0001
c
Race/ethnicity (%) 0.0002
African American 74 38 67
Caucasian 18 48 25
Hispanic 5 7 8
Asian 1 6 0
Other 2 1 0
Sex (%) 0.1
% Male 63 78 67
% Female 37 22 33
BMI (kg/m
2)3 1 612 6 613 5 61 ,0.0001
a
0.001
b
,0.0001
c
Systolic BP (mmHg) 131621 2 3 611 2 7 630 . 0 0 2
a
0.16
b
0.13
c
Diastolic BP (mmHg) 80617 7 617 7 61 0.18
ACE or ARB use (%) 49% 20% 64% ,0.0001
a
0.09
b
,0.0001
c
Duration diabetes (yrs) 6.860.7 6.260.8
{ 0.53
Current insulin use (%) 29 21 0.32
Hemoglobin A1c 7.160.2 7.860.3 0.03
Duration HIV (yrs) 13611 4 61 0.38
CD4 (cells/mL) 588632 522630 0.13
HIV VL ,50 copies/mL (%) 56 81 0.0007
Current use ARV therapy (%) 77 94 0.002
ARV therapy naı ¨ve (%) 15 1 0.0006
Duration ARV therapy (yrs) 7.760.6 7.960.5 0.8
Serum creatinine (mg/dL) 0.9660.02 0.9860.02 0.9460.02 0.45
Glomerular Filtration Rate (mL/min) 82.062.3 88.162.2 82.661.9 0.09
Urinary albumin/creatinine ratio (mg/g) 117.5636.8 17.765.4 59.9632.2 ,0.0001
a
0.1
b
0.04
c
{data available on 43 subjects,
a– p-value for HIV+ diabetes+ versus HIV+.
b– p value for HIV+ diabetes+ versus diabetes+.
c– p value for HIV+ versus diabetes+.
doi:10.1371/journal.pone.0024610.t001
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We determined homocysteine, cystatin C, IL-6 and high
sensitivity CRP levels in the subjects with HIV infection and
diabetes to evaluate whether these markers were indicative of
albuminuria in this at risk population. There was no significant
correlation between the biomarkers and the urinary albumin/
creatinine ratio, and similarly, there was no difference in the mean
levels of each biomarker in those with and without albuminuria
(data not shown). There was a significant inverse correlation
between cystatin C and GFR (r=20.52, p,0.0001). BMI was
also positively correlated with hsCRP (r=0.28, p=0.02) but there
was no significant association between BMI and urinary albumin/
creatinine ratio.
HIV and Antiretroviral Therapy in Association with
albuminuria
In order to evaluate potential associations between HIV specific
characteristics and albuminuria, we completed a sub-analysis of all
HIV-infected subjects. There was no difference in CD4+ T-cell
count, duration of HIV, or total years of ARV exposure between
those with and those without albuminuria (Table 2). The urinary
albumin/creatinine ratio correlated significantly with HIV viral
load (r=0.28, p=0.0005). There was no significant interaction
between HIV viral load and diabetes status with regard to urinary
albumin/creatinine ratio in the HIV-infected subjects. HIV-
infected subjects on an ARV regimen containing abacavir were
more likely to have albuminuria (% albuminuria for those on
abacavir 37% vs. 19% in those not on abacavir, p=0.03). There
were no other significant differences in albuminuria by current
ARV use.
HIV-infected subjects with albuminuria had significantly
greater cumulative exposure to abacavir (30.4 mos vs. 10.9 mos,
p=0.01) and less exposure to indinavir (5.8 mos vs. 15.2 mos,
p=0.02) compared to those without albuminuria. Cumulative
exposure of other antiretroviral agents, including tenofovir, did not
differ by albuminuria. These observations were replicated in
univariate regression analysis of cumulative duration of specific
ARV exposures and urinary albumin/creatinine ratio, where only
abacavir and indinavir showed significant relationships to
albumin/creatinine ratio (abacavir mos r=0.19, p=0.02; indina-
vir mos r=20.17, p=0.03). In a multivariate logistic regression
analysis which included age, race, sex, BMI, blood pressure, and
ACE/ARB use, the diagnosis of diabetes (p=0.003), higher HIV
viral load (p=0.04) and cumulative exposure to abacavir
(p=0.001) were all significant independent predictors of albumin-
uria in HIV-infected subjects. Indinavir exposure was no longer
significant (p=0.08). The association between albuminuria and
abacavir (p=0.002) and the diagnosis of diabetes (p=0.003)
remained significant after further adjustment for total years of
ARV exposure. Each of the statistical analyses was repeated
excluding the 10 subjects with macroalbuminuria, and there were
no changes in statistical significance with regard to the major
findings (data not shown).
Discussion
Though albuminuria is considered an important complication
of both diabetes and HIV, our study is the first to report on the
prevalence of albuminuria among individuals affected by both
diseases. We found that HIV and diabetes have additive effects in
regards to early kidney dysfunction. This was demonstrated by the
presence of albuminuria identified in 34% of HIV-infected
diabetic subjects compared to control groups with HIV alone
(13%) or diabetes alone (16%).
In the present study, the effects of HIV and diabetes on
albuminuria were significant even after the effects of age, race,
BMI, blood pressure and ACE/ARB use, factors known to
influence albuminuria, were taken into account. The prevalence of
albuminuria among the HIV-infected subjects without diabetes
was similar to the 11% identified by Szczech and colleagues in a
similar HIV-infected cohort [13]. The prevalence of albuminuria
noted among the uninfected controls with diabetes was slightly
lower than other large diabetes cohort studies [14,16], but the
duration of diabetes in our study population was relatively short by
comparison and may account for this difference. We did not
identify an increased prevalence of albuminuria related to African
American race or Hispanic ethnicity as seen in prior large US
population surveys [17]. The percentage of African American
Figure 1. Prevalence of microalbuminuria in HIV-infected subjects with diabetes (HIV/DM), HIV-infected subjects without diabetes
(HIV) and subjects with diabetes without HIV infection (DM). P values represent pairwise comparisons by chi-square.
doi:10.1371/journal.pone.0024610.g001
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it may have been difficult to identify independent influences based
on race. Among those participants with HIV, we did not find a
relationship between albuminuria and CD4+ T-cell count;
however, there was a positive correlation between HIV viral load
and levels of albuminuria. The increased prevalence of HIV
viremia among the HIV-infected subjects with diabetes may have
contributed, at least in part, to the high prevalence of albuminuria
observed in this group. These data suggest that active HIV
infection may contribute to a broad spectrum of kidney injury,
ranging from microalbuminuria to more severe injury such as
HIV-associated nephropathy [18]. Alternatively, viremia may be a
marker of medication non-adherence which itself may play a role
in albuminuria in individuals with HIV and diabetes.
Glycemic control is one potential contributor to microalbumin-
uria in the setting of diabetes. Despite the lower HbA1c levels
noted in the HIV-infected subjects with diabetes compared to
controls with diabetes alone, we and others have shown that
HbA1c tends to underestimates glycemia in HIV[15,19]. Further,
HIV-infected participants with diabetes were less likely to be on an
ACE or ARB medication compared to participants with diabetes
alone. Therefore, practice disparities in health management of
glycemic control and blood pressure in the setting of HIV and
diabetes may contribute to the increased rates of microalbumin-
uria observed in this group.
Of interest, we found that HIV-infected subjects with
albuminuria had significantly greater cumulative exposure to
abacavir and less exposure to indinavir when compared to those
without albuminuria. Analysis of exposure to other ARV agents
did not show significance in this regard. The inverse association
between indinavir and albuminuria may be secondary to
confounding. Namely, clinicians may have been disinclined to
prescribe or may have discontinued indinavir for patients with
perceived risk of kidney disease due to the known association
between indinavir use and urinary crystal formation. Similarly,
one might argue that increased abacavir exposure in those with
albuminuria was observed due to confounding in prescribing
practices. For example, clinicians may have preferentially used
abacavir rather than tenofovir in individuals with risk factors for
kidney disease. However the present data do not support this
consideration because cumulative, current and any exposure to
tenofovir did not differ between those with albuminuria and those
without.
Recent use of abacavir has been implicated in chronic kidney
disease[20]. Here we noted increased albuminuria in association
with both current and cumulative abacavir exposure, which may
represent a relationship between abacavir and early endothelial
injury. Recent large cohort studies and randomized trials have
implicated abacavir in the development of cardiovascular disease
in HIV-infected adults [21,22]. However chronic kidney disease is
also linked to cardiovascular disease events in HIV, further
complicating the association between abacavir and vascular events
[23].
Microalbuminuria is often considered a harbinger of more
significant vascular disease; therefore the current observation
linking albuminuria to abacavir exposure may represent
Table 2. Comparison of HIV-Related Characteristics and Cumulative ARV Exposure in HIV-infected Subjects with and without
Albuminuria.
Albuminuria (n=36) No Albuminuria (n=119) p-value
Duration HIV (y) 13.161.0 13.760.6 0.6
Duration ARV exposure (y) 7.460.9 7.960.4 0.6
CD4 T cell count 498642 570626 0.15
HIV viral load (log copies/ml) 2.5560.2 2.1060.08 0.046
Cumulative NRTI Exposure
Abacavir (mos) 30671 1 62 0.01
Didanosine (mos) 15661 1 62 0.6
Emtricitabine (mos) 8621 2 62 0.09
Lamivudine (mos) 53686 3 64 0.3
Stavudine (mos) 21662 1 63 0.99
Tenofovir (mos) 19642 2 62 0.5
Zalcitabine (mos) 4621 60.2 0.2
Zidovudine (mos) 30664 2 64 0.09
Cumulative PI Exposure
Atazanavir (mos) 7628 61 0.6
Indinavir (mos) 6631 5 63 0.01
Lopinavir (mos) 13641 4 62 0.8
Nelfinavir (mos) 13651 2 62 0.9
Ritonavir (mos) 19651 6 62 0.6
Saquinavir (mos) 5623 61 0.5
Cumulative NNRTI Exposure
Efavarenz (mos) 19652 2 63 0.6
Nevirapine (mos) 12658 62 0.5
doi:10.1371/journal.pone.0024610.t002
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vestigation by Hsue and colleagues found that current abacavir
use was independently associated with impaired endothelial
function as measured by flow mediated vasodilation [24]. This
effect was not readily explained by traditional cardiovascular
disease risk factors, nor was it related to other HIV specific
measures such as CD4+ T-cell count and duration of ARV
therapy.
Studies of type 2 diabetes, in the absence of HIV infection, have
observed associations between inflammatory markers such as IL-6
and CRP and degree of albuminuria [25,26,27]. In the present
study we did not identify significant correlations between hsCRP
or IL-6 and albuminuria among HIV-infected diabetic subjects.
The relatively small sample size may limit our ability to detect such
relationships. Alternatively, non-inflammatory processes such as
medication effects and direct viral toxicity may be stronger
mediating factors of albuminuria in this unique population.
Further, 30% of the HIV-infected diabetic subjects had hsCRP
levels above the limit of the assay (.5.0 microgram/ml), indicating
a relatively high level of inflammation and possibly limiting our
ability to detect linear relationships between hsCRP and other
variables.
Interpretation of the current findings is limited due to the cross-
sectional nature of the study and therefore identified associations
cannot be used to assign causality. There is also a possibility for
selection bias in that participants concerned with diabetes and or
kidney function may have been more likely to agree to participate.
In addition, we performed a single measure of urinary albumin
and creatinine levels, whereas multiple determinations would
provide a more accurate estimate of the true prevalence of
albuminuria in this population [12]. Currently, one of the largest
studies estimating the prevalence of microalbuminuria in HIV also
used a single determination [13] and the prevalence estimate of
11% was similar to the 8.7% found in a recent HIV study which
utilized 3 urine measurements [12].
In summary, we found that the prevalence of albuminuria in
individuals with HIV and diabetes was two fold greater than that
of individuals with either disease alone. The albuminuria was
associated with traditional risk factors such as increasing age and
blood pressure, poor glycemic control, but was also independently
associated with increased exposure to abacavir and HIV viral load.
Though screening for microalbuminuria and recommendations
for its management are well-defined for diabetic patients, there are
no recommendations specific to HIV. High quality studies that
obtain serial determinations of urinary albumin/creatinine ratios
in HIV-infected patients both with and without diabetes are
needed to better estimate the prevalence of this problem. The high
estimate of albuminuria among HIV-infected, diabetic subjects
observed with a single determination in this study is concerning
and further research on the persistence, progression and
management of albuminuria in this unique at-risk population is
needed.
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